Gaboxadol
Phase 3Small molecule
LundbeckGaboxadol is one of 116 small molecule programs targeting Insomnia. It is currently in Phase 3.
4
Indications
12
Total Trials
0
Active Trials
115
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Fetzima
AbbViePhase 3
Lisdexamfetamine Dimesylate
TakedaPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Rapastinel
AbbViePhase 3
DVS-233
PfizerPhase 3
TC-5214
AstraZenecaPhase 3
Gaboxadol
LundbeckPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Insomnia8 trials
Show 5 more trials
Fragile X Syndrome2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gaboxadol. EMBL-EBI & Wellcome Sanger Institute.
- [4]